2016 editions
- December 2016
Joao Incio on mechanisms to explain why obesity promotes cancer. - November 2016
Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer. - October 2016
Ruth Muschel on a new target for treatments for colorectal cancer. - September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer. - August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells. - July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer. - June 2016
Key advances in clinical trials. - May 2016
Mark Lemmon on the underlying biochemistry of cancer. - April 2016
Roger Stupp on using alternating electric fields as treatment. - March 2016
Charlotte Vrinten on public perception of deaths from cancer. - February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS). - December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
EJC News Focus – June 2016
Key Advances in Clinical Trials
International Clinical Trials Day, on May 20th is an opportunity for clinical researchers and the public to celebrate progress in clinical research. It commemorates the day in 1747 when James Lind started a clinical trial on the causes of scurvy and laid the foundations for modern research.
At University College London (UK), the Institute of Clinical Trials and Methodology (ICTM) devoted the day to key advances, many in cancer research. The dramatic increase in cancer treatments poses both opportunities and challenges, Max Parmar, Director of ICTM, tells Helen Saul in this month's EJC News Focus. Statistician Melissa Spears outlines one solution in the prostate cancer trial STAMPEDE, which uses a multi-arm multi-stage (MAMS) platform. Helen Meadows describes research into rare cancers and Sara Ghorashian discusses ground-breaking research into chimeric antigen receptors (CARs).